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AntitubercularAbstract In the present study, two new series of pyrazolines (3a–h & 4a–h) were synthesized start-
ing from p-acetamidophenol (paracetamol) and evaluated for their antibacterial, antifungal and
antitubercular activities. Chalcones (2a–h) prepared by condensing 3-acetyl-4-hydroxyphenyl acet-
amide (1) with different aromatic aldehydes were reacted with phenyl hydrazine and isonicotinic
acid hydrazide to obtain phenyl-pyrazolines (3a–h) and isoniazid-pyrazolines (4a–h), respectively.
The structures of the synthesized compounds were conﬁrmed by spectral and microanalysis studies.
Newly prepared pyrazoline compounds exhibited signiﬁcant antibacterial activity against the organ-
isms Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa when compared with the
standard antibiotic Ciproﬂoxacin. Compound 4g showed potent antibacterial activity against P.
aeruginosa and S. aureus (MIC-3.12 lg/mL), however, against E. coli compound 3d, 4c, 4d, 4f &
4g were found to have an MIC of 6.25 lg/mL. Antifungal activity of compound 4d against Candida
albicans and Aspergillus niger (MIC-3.12 lg/mL) was found to be better than the standard drug
Ketoconazole. The results of antitubercular activity of the synthesized compounds against
Mycobacterium tuberculosis H37Rv by the agar microdilution method are quite promising. The
578 A. Ahmad et al.antitubercular activity of compounds 4c, 4d & 4g (MIC-3.12 lg/mL) was found to be superior than
that of the reference drug Streptomycin which showed MIC equal to 6.25 lg/mL. It was observed
that pyrazolines with chloro, nitro or methoxy substituent showed better activity. Also, the pyraz-
olines derived from isoniazid (4a–h) were found to be better in their antibacterial, antifungal and
antitubercular action than those derived from phenyl-hydrazine (3a–h).
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Infection diseases such as bacterial and fungal infections have
been reported to increase dramatically worldwide in recent
times and one of the major causes is suppressed immunity
[1]. Suppression of immunity due to various reasons such as
malignancy, immunosuppressive therapies, HIV-infection, sur-
geries, old age etc. is a plausible cause that places patients at
high risk for catching microbial infections. The situation is fur-
ther worsened by increasing incidence of microbial resistance
to the majority of antibiotics available today. Antimicrobial
resistance is a major concern and threat to the public health
and warrants development of novel and effective antibiotics
to combat drug resistance [2]. Currently available antifungal
agents in the market are fewer in number and majority of them
have potential disadvantages with regard to their toxicity,
spectrum, lack of oral formulations, few drug targets, pharma-
cokinetics and higher cost [3].
Tuberculosis (TB) is one of the most important chronic
communicable bacterial diseases caused by Mycobacterium
tuberculosis. TB is one of the major causes of morbidity and
mortality throughout the world. Approximately 32% of the
world’s population is currently living with this infectious dis-
ease. It is a fatal disease and one of the leading causes of the
death all over the world especially in the developing countries
like India. It is also believed to be the leading cause of death
among HIV positive peoples. Present anti-tubercular drugs
are quite effective in the treatment of TB but resistance to these
drugs byM. tuberculosis strains is on the rise which is a growing
concern among scientiﬁc community worldwide. New antitu-
bercular compounds/structures are urgently needed in the pres-
ent situation because very few agents belonging to ﬁrst line (e.g.
rifabutin) or second line drugs (e.g. capreomycin, levoﬂoxacin)
have become available for the treatment of this disease since the
introduction of rifampicin in 1966 [4]. To solve these issues,
there is an urgent need to develop novel alternative, safe and
potent drugs with a broader spectrum of antimicrobial activity
[5]. Various Nitrogen containing heterocyclic compounds such
as pyrazolines, pyridazinones and pyrrolones have been studied
extensively for the development of pharmaceutically important
antimicrobial agents. These nitrogen containing compounds
have played an important role in drug discovery owing to their
diverse pharmacological actions. Pyrazolines are even more
special due to their marked physiological and pharmacological
activity and distinct functions. Pyrazoline derivatives were
reported to possess numerous prominent pharmacological
activities; antimicrobial–antibacterial and antifungal [6–9],
antiamoebic [10], anti-TB [11], anti-HIV [12], anticancer [13],
antidepressant and anticonvulsant [14].
The pyrazoline ring contains N–N bond linkage which is
considered to be the key factor in their biological actions.Natural abundance of compounds having N–N bonds is less
because these bonds are constructed with a great difﬁculty
by living organism [15,16]. Isoniazid is a well known pharma-
cologically active antitubercular compound; therefore, we
thought to synthesize pyrazoline derivatives by condensing
INH and p-acetamidophenol and investigate their antibacte-
rial, antifungal and antitubercular potential.2. Experimental
2.1. Measurements
All the reagents and solvents were of LR grade and were
purchased locally from S.D. Fine (Mumbai, India), Merck
(Mumbai, India) and CDH (New Delhi, India). Melting points
were recorded in liquid parafﬁn bath using open end capillaries
and are uncorrected. The IR spectra were recorded on a
Thermo Nicolet avatar 330-FT-IR spectrophotometer using
KBr pellets. Bruker spectrospin DPX-300 MHz was used to
record 1H NMR spectra of the synthesized compounds in
CDCl3; TMS was used as an internal standard and chemical
shift values (d) are expressed as parts per million (ppm). Fol-
lowing abbreviations were used do describe the splitting pat-
terns of peaks in proton NMR spectra: s-singlet; d-doublet;
dd-double doublet; m-multiplet. Mass spectral data for title
compounds were recorded on a JEOL JMS-D 300 instrument.
Perkin-Elmer 240 analyzer was used to perform elemental
analyses (C, H, N) and were found in the range of ±0.4%
for each analyzed element. Progress of reactions was moni-
tored on thin-layer chromatography (TLC) using silica gel G
(Merck) as stationary phase in the solvent system-Toluene:
Ethyl acetate: Formic acid (5:4:1, v/v/v); iodine chamber,
and UV lamp were used for visualization of TLC spots.
2.2. Synthesis of the compounds
2.2.1. Synthesis of 3-acetyl-4-hydroxyphenyl acetamide (1)
A mixture of p-acetamidophenol (0.322 mol) in dry pyridine
(10 mL) and acetic anhydride (5 mL) was heated on water bath
for 3 h. It was cooled and poured onto crushed ice, ﬁltered,
washed with water and crystallized from acetone. The product
(0.103 mol) so obtained was mixed with anhydrous AlCl3 (3 g)
and heated in oil bath at 118 C for 2 h. After completion of
reaction, the reaction mixture was decomposed with dil. HCl
(4%, 25 mL) which yielded a brownish mass. It was ﬁltered,
washed with water, dried and crystallized from petroleum
ether: diethyl ether mixture (1:1) to get TLC pure compound
1. Yield 78%, m.p. 160 C. Rf 0.81. 1H NMR (CDCl3)
d= 2.15 (s, 3H, NHOCH3), 2.59 (s, 3H, COCH3), 7.04 (d,
1H, H-3), 8.12 (d, 2H, H-4, 6), 9.66 (s, 1H, OH), 12.10 (s,
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(C10H11NO3); Calcd. C, 62.17; H, 5.74; N 7.25; found C,
62.22; H, 5.68; N, 7.10%.
2.2.2. Synthesis of chalcones
2.2.2.1. General procedure for the synthesis of N-{4-hydroxy-3-
[(3-substituted phenyl)-2-propen-1-one] phenyl}-acetamides
(2a–h). A mixture of 3-acetyl-4-hydroxyphenyl acetamide 1
(0.01 mol) in ethanol (20 mL), aromatic aldehyde (equimolar;
0.01 mol) and aq. potassium hydroxide (5 mL, 30% w/v) was
stirred on a magnetic stirrer for 5 h at ambient temperature
and then left aside overnight at room temperature. It was
poured into cold water and neutralized with dilute hydrochlo-
ric acid. The precipitates so obtained were ﬁltered, washed
with water, dried and crystallized from ethanol to get 2a–h.
Formation of chalcone was conﬁrmed by adding conc. Sulfuric
acid to the compounds 2a–h, which produced a red color [17] .
2.2.2.2. N-{4-hydroxy-3-[3-phenylprop-2-enoyl]phenyl}acetam-
ide (2a). Yield 63%, m.p. 92 C. Rf 0.66. 1H NMR (CDCl3)
d= 2.19 (s, 3H, NHCOCH3), 6.98 (d, 1H, H-3), 7.28–7.46
(m, 5H, phenyl), 7.59 & 8.31 (d, each H, CH‚CH), 8.22 (d,
2H, H-4, 6), 9.53 (s, 1H, OH), 11.47 (s, 1H, CONH). MS
[EI] m/z 281. Elemental analysis (C17H15NO3); Calcd. C,
72.58; H, 5.37; N, 4.98; found C, 72.36; H, 5.28; N, 5.10%.
2.2.2.3. N-{4-hydroxy-3-[3-(3-chlorophenyl) prop-2-enoyl]
phenyl}acetamide (2b). Yield 57%, m.p. 112 C. Rf value:
0.63. 1H NMR (CDCl3) d= 2.18 (s, 3H, NHCOCH3), 7.02
(d, 1H, H-3), 7.35–7.49 (m, 4H, H-20,40,50,60), 7.57 & 8.33 (d,
each H, CH‚CH), 8.25 (d, 2H, H-4,6), 9.67 (s, 1H, OH),
11.39 (s, 1H, CONH). MS [EI] m/z 315. Elemental analysis
(C17H14ClNO3); Calcd. C, 64.67; H, 4.47; N, 4.44; found C,
64.58; H, 4.42; N, 4.28%.
2.2.2.4. N-{3-[3-(4-chlorophenyl) prop-2-enoyl]-4-hydroxy-
phenyl}acetamide (2c). Yield 59%, m.p. 92–94 C. Rf 0.65.
1H NMR (CDCl3) d= 2.20 (s, 3H, NHCOCH3), 6.96 (d,
1H, H-3); 7.47 & 7.82 (d, each, A2B2, p-chloro phenyl), 7.56
& 8.28 (d, each H, CH‚CH), 8.32 (d, 2H, H-4,6), 9.61 (s,
1H, OH), 11.62 (s, 1H, CONH). MS[EI] m/z 315. Elemental
analysis (C17H14ClNO3); Calcd. C, 64.67; H, 4.47; N, 4.44;
found C, 64.45; H, 4.51; N, 4.35%.
2.2.2.5. N-{3-[3-(2,4-dichlorophenyl)prop-2-enoyl]-4-hydroxy-
phenyl}acetamide (2d). Yield 47%, m.p. 144–145 C. Rf 0.51.
1H NMR (CDCl3) d= 2.18 (s, 3H, NHCOCH3), 7.01 (d,
1H, H-3); 7.29–7.37 (m, 2H, H-50,60), 7.48 (s, 1H, H-30), 7.58
& 8.86 (d, each, CH‚CH), 8.33 (d, 2H, H-4,6), 9.65 (s, 1H,
OH), 11.48 (s, 1H, CONH). MS[EI] m/z 350. Elemental anal-
ysis (C17H13Cl2NO3); Calcd. C, 58.31; H, 3.74; N, 4.00; found
C, 58.17; H, 3.82; N, 3.84%.
2.2.2.6. N-{4-hydroxy-3-[3-(2-hydroxyphenyl)prop-2-enoyl]
phenyl}acetamide (2e). Yield 52%, m.p. 140 C. Rf 0.60. 1H
NMR (CDCl3) d= 2.19 (s, 3H, NHCOCH3), 6.98 (d, 1H,
H-3); 7.30–7.52 (m, 3H, H-40,50,60), 7.74 (dd, 1H, H-30), 7.59
& 8.38 (d, each, CH‚CH), 8.39 (d, 2H, H-4,6), 9.57 (s, 1H,
OH), 10.89 (s, 1H, CONH). MS [EI] m/z 297; Elemental anal-
ysis (C17H15NO4); Calcd. C, 68.68; H, 5.09; N, 4.71; found C,
68.52; H, 4.94; N, 4.66%.2.2.2.7. N-{4-hydroxy-3-[3-(2-nitrophenyl) prop-2-enoyl]
phenyl}acetamide (2f). Yield 57%, m.p. 102 C. Rf 0.67. 1H
NMR (CDCl3) d= 2.21 (s, 3H, NHCOCH3), 7.03 (d, 1H,
H-3); 7.35–7.60 (m, 3H, H-40,50,60), 7.71 (dd, 1H, H-30), 7.58
& 8.35 (d, each, CH‚CH), 8.44 (d, 2H, H-4,6), 9.62 (s, 1H,
OH), 11.25 (s, 1H, CONH). MS [EI] m/z 327. Elemental anal-
ysis (C17H14N2O5); Calcd. C, 62.57; H, 4.32; N, 8.59; found C,
62.61; H, 4.29; N, 8.45%.
2.2.2.8. N-{4-hydroxy-3-[3-(4-nitrophenyl)prop-2-enoyl]phe-
nyl}acetamide (2g). Yield 55%, m.p. 146 C. Rf 0.70. 1H
NMR (CDCl3) d ppm: 2.18 (s, 3H, NHCOCH3), 6.94 (d,
1H, H-3); 7.39 & 7.85 (d, each, A2B2, p-chloro phenyl), 7.51
& 8.24 (d, each, CH‚CH), 8.32 (d, 2H, H-4,6), 9.85 (s, 1H,
OH), 11.93 (s, 1H, CONH). MS [EI] m/z 326. Elemental anal-
ysis (C17H14N2O5); Calcd. C, 62.57; H, 4.32; N, 8.59; found C,
62.36; H, 4.18; N, 8.53%.
2.2.2.9. N-{4-hydroxy-3-[3-(3-methoxyphenyl)prop-2-enoyl]
phenyl}acetamide (2h). Yield 78%, m.p. 118–120 C. Rf 0.68.
1H NMR (CDCl3) d= 2.21 (s, 3H, NHCOCH3), 3.63 (s,
3H, OCH3), 6.96 (d, 1H, H-3); 7.22–7.56 (m, 4H, H-
20,40,50,60), 7.58 & 8.26 (d, each, CH‚CH), 8.41 (d, 2H, H-
4,6), 9.53 (s, 1H, OH), 10.81 (s, 1H, CONH). MS [EI] m/z
311. Elemental analysis (C18H17NO4); Calcd. C, 69.44; H,
5.50; N, 4.50; found C, 69.27; H, 5.42; N, 4.55%.
2.2.3. Synthesis of pyrazolines (3a–h)
2.2.3.1. General procedure for the synthesis of N-[3-(5-substi-
tuted phenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-4-hydroxy
phenyl]acetamides (3a–h). To an ethanolic solution of chal-
cones 2a–h (0.01 mol; 20 mL), hydrazine hydrate (0.02 mol;
99%) was added drop wise and the reaction mixture was
reﬂuxed for 8–10 h. After completion of the reaction, the con-
tents were concentrated and poured onto crushed ice (approx.
100 g). Solid mass was obtained which was ﬁltered, washed
with plenty of cold water and recrystallized from ethanol to
get the pure product pyrazolines 3a–h. Purity of the compound
was checked on TLC plates in the solvent system-benzene:
methanol (8:2).
2.2.3.2. N-[3-(1,5-diphenyl-4,5-dihydro-1H-pyrazol-3-yl)-4-
hydroxyphenyl]acetamide (3a). Yield 61%, m.p. 128–129 C.
Rf 0.61.
1H NMR (DMSO-d6) d= 2.46 (s, 3H, NHCOCH3),
3.32 (dd, 1H, Ha), 3.35 (dd, 1H, Hb), 5.03 (dd, 1H, Hx),
6.86–8.07 (complex m, 13H, Ar-H), 9.90 (s, 1H, OH), 11.41
(s, 1H, CONH). IR (KBr, cm1): 3465 (N–H), 3315 (OH),
1689 (C‚O), 1568 (C‚N). MS [EI] m/z 371 (M+). Elemental
analysis (C23H21N3O2); Calcd. C, 74.37; H, 5.70; N, 11.31;
found C, 74.18; H, 5.56; N, 11.35%.
2.2.3.3. N-{3-[5-(3-chlorophenyl)-1-phenyl-4,5-dihydro-1H-
pyrazol-3-yl]-4-hydroxyphenyl} acetamide (3b). Yield 55%,
m.p. 117 C. Rf 0.64. 1H NMR (DMSO-d6) d= 2.51 (s, 3H,
NHCOCH3), 3.53 (dd, 1H, Ha), 3.96 (dd, 1H, Hb), 5.03 (dd,
1H, Hx), 6.82–8.04 (complex m, 12H, Ar–H), 9.43 (s, 1H,
OH), 10.61 (s, 1H, CONH). IR (KBr, cm1): 3413 (N–H),
3306 (O–H), 1661 (C‚O), 1578 (C‚N), 742 (C–Cl). MS
[EI] m/z 405 (M+). Elemental analysis (C23H20ClN3O2); Calcd.
C, 68.06; H, 4.97, N; 10.35; found C, 67.85; H, 5.02; N,
10.26%.
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pyrazol-3-yl]-4-hydroxyphenyl} acetamide (3c). Yield 58%,
m.p. 108–110 C. Rf 0.67. 1H NMR (DMSO-d6) d= 2.49 (s,
3H, NHCOCH3), 3.55 (dd, 1H, Ha), 3.95 (dd, 1H, Hb), 5.03
(dd, 1H, Hx), 6.81–8.02 (complex m, 12H, Ar-H), 9.46 (s,
1H, OH), 10.63 (s, 1H, CONH). IR (KBr, cm1): 3413 (N–
H), 3305 (O–H), 1668 (C‚O), 1588 (C‚N), 735 (C–Cl). MS
[EI] m/z 405 (M+). Elemental analysis (C23H20ClN3O2): Calcd.
C, 68.06; H, 4.97; N, 10.35; found C, 67.90; H, 4.84; N,
10.28%.
2.2.3.5. N-{3-[5-(2,4-dichlorophenyl)-1-phenyl-4,5-dihydro-1H-
pyrazol-3-yl]-4-hydroxyphenyl} acetamide (3d). Yield 56%,
m.p. 121 C, Rf 0.63, 1H NMR (DMSO-d6) d= 2.48 (s, 3H,
NHCOCH3), 3.49 (dd, 1H, Ha), 3.88 (dd, 1H, Hb), 5.05 (dd,
1H, Hx), 6.94–8.08 (complex m, 11H, Ar–H), 9.92 (s, 1H,
OH), 10.54 (s, 1H, CONH). IR (KBr, cm1): 3427 (N–H),
3219 (O–H), 1654 (C‚O), 1581 (C‚N); 750 (C–Cl). MS
[EI] m/z 439 (M+). Elemental analysis (C23H19Cl2N3O2);
Calcd. C, 62.74; H, 4.35; N, 9.54; found C, 62.56; H, 4.28;
N, 9.35%.
2.2.3.6. N-{4-hydroxy-3-[5-(2-hydroxyphenyl)-1-phenyl-4,5-
dihydro-1H-pyrazol-3-yl]phenyl} acetamide (3e). Yield 44%,
m.p. 102 C. Rf 0.61. 1H NMR (DMSO-d6) d= 2.47 (s, 3H,
NHCOCH3), 3.48 (dd, 1H, Ha), 4.04 (dd, 1H, Hb), 5.02 (dd,
1H, Hx), 6.39–7.68 (complex m, 12H, Ar–H), 10.02 (s, 1H,
OH), 10.46 (s, 1H, CONH). IR (KBr, cm1): 3445 (N–H),
3304 (O–H), 1704 (C‚O), 1572 (C‚N). MS [EI] m/z 387
(M+). Elemental analysis (C23H21N3O3); Calcd. C, 71.30; H,
5.46; N, 10.85; found C, 71.13; H, 5.38; N, 10.74%.
2.2.3.7. N-{4-hydroxy-3-[5-(2-nitrophenyl)-1-phenyl-4,5-dihy-
dro-1H-pyrazol-3-yl]phenyl} acetamide (3f). Yield 61%, m.p.
142 C. Rf 0.65. 1H NMR (DMSO-d6) d= 2.47 (s, 3H, NHC-
OCH3), 3.58 (dd, 1H, Ha), 3.91 (dd, 1H, Hb), 5.12 (dd, 1H,
Hx), 6.38–7.67 (m, 9H, Ar–H), 8.02–8.21 (m, 3H, Ar–H),
9.34 (s, 1H, OH), 10.56 (s, 1H, CONH). IR (KBr, cm1):
3461 (N–H), 3315 (O–H), 1717 (C‚O), 1583 (C‚N). MS
[EI] m/z 416 (M+). Elemental analysis (C23H20N4O4); Calcd.
C, 66.34; H, 4.84; N 13.45; found C, 66.25; H, 4.76; N,
13.60%.
2.2.3.8. N-{4-hydroxy-3-[5-(4-nitrophenyl)-1-phenyl-4,5-dihy-
dro-1H-pyrazol-3-yl]phenyl} acetamide (3g). Yield 53%,
m.p. 131–132 C. Rf 0.68. 1H NMR (DMSO-d6) d= 2.48 (s,
3H, NHCOCH3), 3.35 (dd, 1H, Ha), 3.95 (dd, 1H, Hb), 4.96
(dd, 1H, Hx), 7.19–7.50 (m, 9H, Ar–H), 8.06–8.28 (m, 3H,
Ar–H), 9.85 (s, 1H, OH), 10.25 (s, 1H, CONH). IR (KBr,
cm1): 3441 (N–H), 3319 (O–H), 1701 (C‚O), 1587 (C‚N).
MS [EI] m/z 416 (M+). Elemental analysis (C23H20N4O4);
Calcd. C, 66.34; H, 4.84; N, 13.45; found C, 66.21; H, 4.78;
N, 13.42%.
2.2.3.9. N-{4-hydroxy-3-[5-(3-methoxyphenyl)-1-phenyl-4,5-
dihydro-1H-pyrazol-3-yl]phenyl} acetamide (3h). Yield 49%,
m.p. 154 C. Rf 0.60. 1H NMR (DMSO-d6) d= 2.44 (s, 3H,
NHCOCH3), 3.56 (dd, 1H, Ha), 3.61 (s, 3H, OCH3), 3.92
(dd, 1H, Hb), 5.11 (dd, 1H, Hx), 6.89–7.94 (complex m, 2H,
Ar–H), 9.53 (s, 1H, OH), 10.52 (s, 1H, CONH). IR (KBr,
cm1): 3432 (N–H), 3321 (O–H), 1691 (C‚O), 1579 (C‚N).
MS [EI] m/z 401 (M+). Elemental analysis (C24H23N3O3);Calcd. C, 71.80; H, 5.77; N, 10.47; found C, 71.53; H, 5.65;
N, 10.41%.
2.2.4. Synthesis of pyrazolines (4a–h)
2.2.4.1. General procedure for the synthesis of N-(4-hydroxy-3-
(1-isonicotinoyl-5-substituted phenyl-4,5-dihydro-1H-pyrazol-3-
yl)phenyl)acetamides (4a–h). An equimolar quantity (3 mmol)
of isoniazid and chalcone 2a–h was reﬂuxed in glacial acetic
acid (15 mL) for 10–12 h. After completion of the reaction
excess of solvent was removed under vacuum and the reaction
mixture was cooled, poured onto crushed ice (approx. 50 g)
and neutralized with dilute ammonia solution. A solid so
obtained was ﬁltered, washed with water and recrystallized
from methanol to get TLC pure compounds 4a–h.
2.2.4.2. N-(4-hydroxy-3-(1-isonicotinoyl-5-phenyl-4,5-dihydro-
1H-pyrazol-3-yl)phenyl)acetamide (4a). Yield 60%, m.p.
128–129 C. Rf 0.65. 1H NMR (DMSO-d6) d= 2.48 (s, 3H,
NHCOCH3), 3.01 (dd, 1H, Ha), 3.34 (dd, 1H, Hb), 5.62 (dd,
1H, Hx,), 6.75–8.75 (complex m, 12H, Ar–H), 9.64 (s, 1H,
OH), 10.28 (s, 1H, CONH). IR (KBr, cm1): 3439 (N–H),
3205 (O–H), 1678 (C‚O), 1594 (C‚N). MS[EI] m/z 400
(M+). Elemental analysis (C23H20N4O3); Calcd. C, 68.99; H,
5.03; N, 13.99; found C, 68.73; H, 4.85; N, 13.92%.
2.2.4.3. N-(3-(5-(3-chlorophenyl)-1-isonicotinoyl-4,5-dihydro-
1H-pyrazol-3-yl)-4-hydroxy-phenyl)acetamide (4b). Yield
54%, m.p. 120 C. Rf 0.68. 1H NMR (DMSO-d6) d= 2.45
(s, 3H, NHCOCH3), 3.19 (dd, 1H, Ha), 3.35 (dd, 1H, Hb),
5.82 (dd, 1H, Hx), 7.03–8.04 (complex m, 11H, Ar–H), 9.78
(s, 1H, OH), 10.41 (s, 1H, CONH). IR (KBr, cm1): 3416
(N–H), 3223 (O–H), 1669 (C‚O), 1574 (C‚N), 736 (C–Cl).
MS[EI] m/z 434 (M+). Elemental analysis (C23H19ClN4O3);
Calcd. C, 63.52; H, 4.40; N, 12.88; found C, 63.60; H, 4.32;
N, 12.76%.
2.2.4.4. N-(3-(5-(4-chlorophenyl)-1-isonicotinoyl-4,5-dihydro-
1H-pyrazol-3-yl)-4-hydroxy-phenyl)acetamide (4c). Yield
58%, m.p. 136 C. Rf 0.67. 1H NMR (DMSO-d6) d= 2.51
(s, 3H, NHCOCH3), 3.60 (dd, 1H, Ha), 3.88 (dd, 1H, Hb),
5.05 (m, 1H, Hx), 7.44–8.84 (complex m, 11H, Ar–H), 9.64
(s, 1H, s, OH), 10.53 (s, 1H, CONH). IR (KBr, cm1): 3412
(N–H), 3231 (O–H), 1675 (C‚O), 1577 (C‚N), 718 (C–Cl).
MS [EI] m/z 434 (M+). Elemental analysis (C23H19ClN4O3);
Calcd. C, 63.52; H, 4.40; N, 12.88; found C, 63.38; H, 4.35;
N, 12.67%.
2.2.4.5. N-(3-(5-(2,4-dichlorophenyl)-1-isonicotinoyl-4,5-dihy-
dro-1H-pyrazol-3-yl)-4-phenyl acetamide (4d). Yield 52%,
m.p. 129 C. Rf 0.64. 1H NMR (DMSO-d6) d= 2.50 (s, 3H,
NHCOCH3), 3.57 (dd, 2H, Ha), 3.89 (dd, 1H, Hb), 4.91 (dd,
1H, Hx), 6.92–8.86 (complex m, 10H, Ar–H), 9.51 (s, 1H,
OH), 10.61 (s, 1H, CONH). IR (KBr, cm1): 3424 (N–H),
3236 (O–H), 1683 (C‚O), 1581 (C‚N), 709 (C–Cl). MS[EI]
m/z 468 (M+). Elemental analysis (C23H18Cl2N4O3); Calcd.
C, 58.86; H, 3.87; N, 11.94; found C, 58.67; H, 3.58; N,
12.02%.
2.2.4.6. N-(4-hydroxy-3-(5-(2-hydroxyphenyl)-1-isonicotinoyl-
4,5-dihydro-1H-pyrazol-3-yl) phenyl)acetamide (4e). Yield
62%, m.p. 151–152 C. Rf 0.68. 1H NMR (DMSO-d6)
Antimicrobial and antitubercular activities of novel pyrazoline derivatives 581d= 2.47 (s, 3H, NHCOCH3), 3.36 (dd, 1H, Ha), 4.02 (dd, 1H,
Hb), 5.31 (dd, 1H, Hx), 6.87–8.69 (complex m, 11H, Ar–H),
9.92 (s, 2H, 2 · OH), 10.54 (s, 1H, CONH). IR (KBr, cm1):
3366 (NH), 3233 (OH), 1704 (C‚O), 1576 (C‚N). MS [EI]
m/z 416 (M+). Elemental analysis (C23H20N4O4); Calcd. C,
66.34; H, 4.84; N, 13.45; found C, 66.12; H, 4.75; N, 13.18%.
2.2.4.7. N-(4-hydroxy-3-(1-isonicotinoyl-5-(2-nitrophenyl)-4,5-
dihydro-1H-pyrazol-3-yl) phenyl)acetamide (4f). Yield 55%,
m.p. 116 C. Rf 0.63. 1H NMR (DMSO-d6) d= 2.48 (s, 3H,
NHCOCH3), 3.39 (dd, 1H, Ha), 3.86 (dd, 1H, Hb), 4.89 (dd,
1H, Hx), 7.68–8.81 (complex m, 11H, Ar–H), 9.77 (s, 1H,
OH), 10.48 (s, 1H, CONH). IR (KBr, cm1): 3392 (N–H),
3218 (O–H), 1698 (C‚O), 1579 (C‚N). MS[EI] m/z 445
(M+). Elemental analysis (C23H19N5O5); Calcd. C, 62.02; H,
4.30; N, 15.72; found C, 61.84; H, 4.19; N, 15.83%.
2.2.4.8. N-(4-hydroxy-3-(1-isonicotinoyl-5-(4-nitrophenyl)-4,5-
dihydro-1H-pyrazol-3yl)phenyl)acetamide (4g). Yield 57%,
m.p. 128 C. Rf 0.61. 1H NMR (DMSO-d6) d= 2.46 (s, 3H,
NHCOCH3), 3.40 (dd, 2H, Ha), 4.03 (dd, 1H, Hb), 5.03 (dd,
1H, Hx), 7.51–8.87 (complex m, 11H, Ar–H), 9.61 (s, 1H,
OH), 10.37 (s, 1H, CONH). IR (KBr, cm1): 3404 (NH),
3211 (OH), 1688 (C‚O), 1584 (C‚N). MS[EI] m/z 445
(M+). Elemental analysis (C23H19N5O5); Calcd. C, 62.02: H,
4.30: N, 15.72; found C, 61.78; H, 4.26; N, 15.61%.
2.2.4.9. N-(4-hydroxy-3-(1-isonicotinoyl-5-(3-methoxyphenyl)-
4,5-dihydro-1H-pyrazol-3-yl)phenyl)acetamide (4h). Yield
60%, m.p. 140–142 C. Rf 0.68. 1H NMR (DMSO-d6)
d= 2.45 (s, 3H, NHCOCH3), 3.34 (dd, 2H, Ha), 3.78 (dd,
1H, Hb), 3.85 (s, 3H, OCH3), 4.81 (dd, 1H, Hx), 7.04–8.82
(complex m, 11H, Ar–H), 9.48 (s, 1H, OH), 10.53 (s, 1H,
CONH). IR (KBr, cm1): 3393 (N–H), 3219 (O–H), 1687
(C‚O), 1582 (C‚N). MS [EI] m/z 430 (M+). ElementalTable 1 Results of antibacterial, antifungal and antitubercular acti
Compound number Antibacterial activitya
S. aureus E. coli P. aeruginos
3a +++ +++ ++
3b +++ +++ +++
3c +++ +++ +++
3d ++++ ++++ ++++
3e +++ +++ +++
3f +++ +++ +++
3g ++++ +++ +++
3h +++ +++ ++++
4a +++ +++ ++
4b +++ +++ +++
4c ++++ ++++ +++
4d ++++ ++++ ++++
4e +++ +++ ++++
4f ++++ ++++ +++
4g ++++ ++++ ++++
4h ++++ +++ +++
Ciproﬂoxacin ++++ ++++ ++++
Ketoconazole nt nt nt
Streptomycin nt nt nt
nt: not tested.
a Zone of inhibition: –:65 mm (insigniﬁcant or no activity); +: 5–9 m
20 mm(strong activity); ++++:P20 mm(very strong activity).analysis (C24H22N4O4); Calcd. C, 66.97; H, 5.15; N, 13.02;
found C, 66.84; H, 4.98; N, 12.85%.
2.3. Antimicrobial studies
2.3.1. Antibacterial activity
The synthesized pyrazoline bearing compounds were screened
for their in vitro antibacterial activity against Staphylococcus
aureus (ATCC-25923), Pseudomonas aeruginosa (ATCC-
27853), and Escherichia coli (ATCC-25922) bacterial strains
at a concentration of 100 lg/mL by the standard cup plate
method [18]. A standard drug (Ciproﬂoxacin) was used for
comparison.
Approximately 20 mL of freshly prepared liquid agar med-
ium was poured into each petridish and then the petridishes
were dried in an incubator at 37 C for duration of 1 h. An
L-shaped spreader was used to spread the standardized culture
of microorganism on each petridish. Cups of approximately
6 mm diameter were made in petridishes using sterile cork
borer and were labeled. A solvent control was also tested to
see the effect of control on the growth of the microbes.
Dimethylsulfoxide (DMSO) was used to prepare the solutions
of synthesized compounds and Ciproﬂoxacin (100 lg/mL).
The prepared solutions were added to each cup in petridishes
and were kept aside in an aseptic area for 1 h to allow diffusion
of the drug/sample, followed by incubation at 37 C for 24 h.
The diameter of the zone of inhibition (in mm) was measured
and the results are shown in Table 1.
The broth dilution technique was employed to determine
the MIC of selected compounds that inhibited growth of at
least one microorganism as per the standard procedure [18].
2.3.2. Antifungal activity
Antifungal activity of the newly synthesized pyrazoline com-
pounds was tested by the agar diffusion assay method againstvity of the pyrazoline compounds.
Antifungal activitya Antitubercular activitya
a C. albicans A. niger M. tuberculosis
+++ +++ +++
+++ +++ ++++
++++ +++ +++
+++ ++++ ++++
+++ +++ +++
+++ +++ +++
+++ +++ ++++
++++ +++ +++
+++ +++ ++
+++ +++ +++
++++ +++ ++++
++++ ++++ ++++
++++ +++ +++
+++ +++ ++++
++++ ++++ ++++
++++ +++ ++++
nt nt nt
++++ ++++ nt
nt nt ++++
m (weak activity); ++: 10–14 mm (moderate activity); +++: 15–
582 A. Ahmad et al.Candida albicans (ATCC-10231) and Aspergillus niger (ATCC-
16404) fungal organisms [19]. Ketoconazole was used as
standard drug for comparison. The Minimum inhibitory con-
centration (MIC) required to inhibit the growth of fungus was
determined.
2.3.3. Antitubercular activity
The antitubercular activity of the synthesized compounds was
evaluated againstM. tuberculosis H37Rv (ATCC 27294) by the
agar microdilution method where twofold dilutions of each
test compound were added into 7H11 agar medium supple-
mented with OADC (oleic acid albumin dextrose catalase)
and organism [20,21]. Streptomycin was used as a standard
drug for comparison. Growth of bacilli was observed after
30 days of incubation at 37 C and minimum inhibitory con-
centration (MIC) was recorded.3. Results and discussion
3.1. Chemistry
The title compounds were synthesized as per the Scheme 1.
Sixteen new pyrazolines analogs (3a–h and 4a–h) were synthe-
sized from chalcones (2a–h), which in turn were prepared fromCH3CONH
CH3CONH
OH
CH3CONH
O
Hx
HbHa
OH
CH3CONH
N N R
CH
O
H2NHN
(1)
(2a-h
(3a-h)
KOH
p-Acetamid
A
A
Scheme 1 Protocol for synthesis of pyp-acetamidophenol (paracetamol). The starting material,
3-acetyl-4-hydroxyphenyl acetamide (1), was prepared by
heating N-(4-hydroxyphenyl) acetamide with acetic anhydride
in the presence of dry pyridine followed by heating with
anhydrous AlCl3. By using Claisen–Schmidt reaction condi-
tions, eight chalcones (2a–h) were synthesized by condensing
3-acetyl-4-hydroxyphenyl acetamide (1) with various aromatic
aldehydes in alkaline medium. These compounds gave red
color with conc. H2SO4 which conﬁrmed formation of
chalcone.
In general, the 1H NMR spectra of chalcones (2a–h)
showed a singlet around d 2.2 which could be assigned to the
methyl protons of the acetamido group (NHCOCH3). The
protons of the tri-substituted phenyl ring (paracetamol ring),
H-30 & H-40,60, appeared as two doublets around d 7.0 and d
8.3, respectively. There appeared two more doublets at d 7.5
and d 8.2, integrating for the protons of chalcone linkage
(–CH‚CH–). The protons of –OH and –CONH– group
appeared as singlets each at d 9.5 and d 11.5, respectively.
Chalcones (2a–h) were then reacted with phenyl hydrazine in
ethanol and with isonicotinic acid hydrazide (isoniazid) in ace-
tic acid to furnish sixteen new pyrazolines (3a–h and 4 a–h). The
structures of the phenyl or isoniazid pyrazolines were
established by IR, 1H NMR, Mass spectral data and elemental
analysis results.OH
OH
CH3
O
R
Hx
HbHa
OH
3CONH
N N
N
O
R
R
HC
N
CONHNH2
)
(4a-h)
o phenol
cetic anhydride
nhyd. AlCl3
razoline derivatives (3a–h and 4a–h).
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(cm1) around 3400 (N–H), 3250–3300 (O–H), 1650–1670
(C‚O) and 1550–1570 (C‚N). 1H NMR spectral data of
the synthesized pyrazolines exhibited a singlet around d 2.4
which was assigned to the methyl protons of the acetamido
group (NHCOCH3). The protons of the pyrazoline ring, Ha,
Hb & Hx, appeared as double doublets around d 3.5, d 4.0
and d 5.0, respectively. A complex multiplet centered around
d 6.5–8.7 could be assigned to the protons of three substituted
aromatic phenyl rings. The protons of –OH and –CONH–
group appeared as singlets each around d 9.5 and d 10.5,
respectively. Molecular ion peaks (M+) were present in rea-
sonable intensities in the mass spectra of pyrazolines. The
molecular ion peak or their fragments having chloro-substitu-
ent(s) were observed as cluster of peaks. Elemental analyses
(C, H, N) were within ±0.4% of theoretical values.
3.2. Antimicrobial evaluation
The synthesized pyrazoline derivatives were evaluated for their
in vitro antimicrobial activities which included antibacterial,
antifungal and antitubercular activities. The inhibition of
microbial growth is routinely used to demonstrate the thera-
peutic efﬁcacy of any subtle change in the efﬁcacy of antibiotic
molecule.
3.2.1. Antibacterial and antifungal activity
Among the screened compounds for antibacterial activity,
compounds 4d & 4g demonstrated the highest activity against
S. aureus with MIC-3.12 lg/mL, which was better than the
standard drug Ciproﬂoxacin (MIC-6.25 lg/mL). Compound
3d, 3g, 4c, 4f & 4h also showed good antibacterial activity
against S. aureus with MIC-6.25 lg/mL, which was found toTable 2 Antibacterial, antifungal and antitubercular activity (MIC
Compound number R Antibacterial activitya
S. aureus E. coli P. ae
3a H 25 25 50
3b 3-Cl 12.5 12.5 12.5
3c 4-Cl 12.5 12.5 12.5
3d 2,4-Cl 6.25 6.25 6.25
3e 2-OH 12.5 12.5 25
3f 2-NO2 12.5 25 25
3g 4-NO2 6.25 12.5 12.5
3h 3-HCO3 12.5 12.5 6.25
4a H 25 25 50
4b 3-Cl 12.5 25 25
4c 4-Cl 6.25 6.25 12.5
4d 2,4-Cl 3.12 6.25 6.25
4e 2-OH 12.5 12.5 6.25
4f 2-NO2 6.25 6.25 12.5
4g 4-NO2 3.12 6.25 3.12
4h 3-HCO3 6.25 12.5 12.5
Standard-1a 6.25 6.25 6.25
Standard-2b nt nt nt
Standard-3c nt nt nt
nt = not tested; MIC =minimum inhibitory concentration.
a Standard-1 = Ciproﬂoxacin.
b Standard-2 = Ketoconazole.
c Standard-3 = Streptomycin.be at par with that of the standard drug. The other compounds
showed low to moderate antibacterial activity against
S. aureus. Against E. coli, compounds 3d, 4c, 4d, 4f & 4g
showed excellent activity with MIC-6.25 lg/mL, which was
found to be at par with that of the standard drug. In the case
of P. aeruginosa, antibacterial activity of compound 4g was
found to be better than that of the standard drug
(MIC-3.12 lg/mL). Five more compounds, 3d, 3h, 4d, 4e &
4g, displayed very good antibacterial activity against
P. aeruginosa with MIC-6.25 lg/mL. Rest of the compounds
exhibited low to moderate activity against P. aeruginosa.
The results of antifungal activity revealed that among the
screened products, compounds 4d & 4g exhibited the most
potent antifungal activity against C. albicans with MIC-
3.12 lg/mL, the activity was found to be better than that of
the standard drug Ketoconazole (MIC-6.25 lg/mL). Com-
pounds 3c, 4c, 4e & 4h showed very good antifungal activity
against C. albicans with MIC-6.25 lg/mL and found at par
with the standard. Against A. niger, antifungal activity of com-
pound 4d (MIC-3.12 lg/mL) was found to be better than that
of the standard drug Ketoconazole (MIC-6.25 lg/mL).
The comparative results of antibacterial & antifungal activ-
ities indicated that the pyrazolines with chloro, hydroxyl or
nitro substituent showed good activity. Further, the pyrazo-
lines derived from isoniazid (4a–h) were better in their antibac-
terial & antifungal actions than those pyrazolines derived from
phenyl-hydrazine (3a–h). All pyrazolines showed a broad spec-
trum of activity and it was worthwhile to note that two isoni-
azid-pyrazolines (4d, 4g) exhibited even better antibacterial &
antifungal activity than the standard drugs.
The active pyrazoline compounds such as 4d & 4g which
exhibited better antibacterial and antifungal activity than the
standard drugs may provide valuable lead molecule(s) for the
treatment of bacterial & fungal infections.in lg/mL) of the title compounds.
Antifungal activityb Antitubercular activityc
ruginosa C. albicans A. niger M .tuberculosis
25 25 25
25 12.5 6.25
6.25 12.5 12.5
12.5 6.25 6.25
25 25 25
12.5 12.5 12.5
12.5 12.5 6.25
6.25 12.5 12.5
25 25 50
12.5 25 25
6.25 6.25 3.12
3.12 3.12 3.12
6.25 12.5 12.5
12.5 12.5 6.25
3.12 6.25 3.12
6.25 12.5 6.25
nt nt nt
6.25 6.25 nt
nt nt 6.25
584 A. Ahmad et al.3.2.2. Antitubercular activity
The results of antitubercular activity of the titled compounds
are highly encouraging and are presented in Tables 1 and 2.
Among the sixteen tested compounds, three compounds, 4c,
4d & 4g, were found to be the most active compounds with
MIC of 3.12 lg/mL and were more active than standard drug
Streptomycin against M. tuberculosis bacteria (MTB). Five
more compounds, 3b, 3d, 3g, 4f & 4h showed excellent antitu-
bercular activity with MIC 6.25 lg/mL and their activity was
at par with that of the standard drug
Among the synthesized compounds, two isoniazid-pyrazo-
lines, N-(3-(5-(2,4-dichlorophenyl)-1-isonicotinoyl-4,5-dihy-
dro-1H-pyrazol-3-yl)-4-hydroxyphenyl)acetamide (4d) and
N-(4-hydroxy-3-(1-isonicotinoyl-5-(4-nitrophenyl)-4,5-dihydro-
1H-pyrazol-3-yl)phenyl)acetamide (4g) emerged as lead
compounds with a broad spectrum of antimicrobial & antitu-
bercular actions.
4. Conclusion
In the present study, 16 new compounds belonging to two ser-
ies of pyrazolines (3a–h & 4a–h) were synthesized and charac-
terized with the help of spectral data (IR, 1H NMR & Mass)
and elemental analysis studies. The title compounds were also
tested for their anticipated antibacterial, antifungal & antitu-
bercular activities against some selected microorganisms.
MIC of all the newly synthesized pyrazoline derivatives was
determined by using standard methods. It was observed that
among the synthesized compounds, the pyrazolines derived
from isoniazid (4a–h) were better in their antimicrobial &
antitubercular action than those pyrazolines derived from
phenyl-hydrazine (3a–h). Two isoniazid-pyrazolines namely,
N-(3-(5-(2,4-dichlorophenyl)-1-isonicotinoyl-4,5-dihydro-1H-
pyrazol-3-yl)-4-hydroxyphenyl) acetamide (4d) and N-(4-
hydroxy-3-(1-isonicotinoyl-5-(4-nitrophenyl)-4,5-dihydro-1H-
pyrazol-3-yl) phenyl) acetamide (4g) emerged as lead
compounds with a broad spectrum of antimicrobial and
antitubercular actions. These compounds could be further
derivatizated to obtain speciﬁc and highly potent antimicrobial
and/or antitubercular agents. Further research work to study
their structure activity relationship and mechanism of actions
is currently under progress in our lab.
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